对初程PRRT后进展的神经内分泌肿瘤患者使用177Lu-DOTATATE挽救性再治疗的疗效、毒性与生存
回顾性分析22例初程177Lu-DOTATATE PRRT后进展的转移性神经内分泌肿瘤患者,接受挽救性PRRT后临床症状、生化、分子影像和形态学影像的疾病控制率分别为68.1%、77.3%、63.6%和63.6%,中位无进展生存期17个月,未出现3/4级血液、肾、肝毒性或AML/MDS。作者认为挽救性PRRT可作为相对安全的治疗选择。
要点
- 挽救性PRRT后分子影像和形态学影像疾病控制率均为63.6%,中位PFS为17个月。
- 挽救性PRRT后最高毒性为2级,未见3/4级血液、肾、肝毒性或AML/MDS。
- 初程PRRT后中位OS未达到,108个月时OS率为68%;挽救性PRRT后18个月OS率为82%。
核心结论
- 对于初程177Lu-DOTATATE PRRT后进展且治疗选择有限的转移性NET患者,挽救性PRRT未出现高级别毒性,作者认为可考虑作为相对安全的治疗选择。
研究设计与样本
- 回顾性研究,纳入22例初程177Lu-DOTATATE PRRT后进展的转移性NET患者(中位年龄55岁,范围38-68岁,男12例、女10例),初程PRRT累积剂量800 mCi(29.6 GBq)至1231 mCi(45.54 GBq),平均964 mCi(35.66 GBq),挽救性PRRT平均剂量170 mCi(6.29 GBq)。
诊断标准与关键数值
- 疗效评估分临床症状、生化、分子影像和形态学影像四类,挽救性PRRT后疾病控制率分别为68.1%、77.3%、63.6%和63.6%;中位PFS为17个月;初程PRRT后中位OS未达到,108个月时OS率68%,挽救性PRRT后18个月OS率82%;毒性按NCI-CTCAE v.5.0评估,最高为2级,可逆性贫血3例(13.5%)、血小板减少1例(4.5%)、肾毒性2例(9%)。
临床应用与阅片要点
- 疗效评估应结合临床症状、生化指标、分子影像和形态学影像四类;毒性评估按NCI-CTCAE v.5.0包括血常规、肾功能和肝功能检查;作者认为挽救性PRRT可考虑作为初程PRRT后进展NET患者的相对安全治疗选择。
局限性
- 原文为回顾性研究。
- 26例患者中4例无完整随访数据,仅22例纳入分析。
- 任何变量与疗效及生存的关联均未观察到显著P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the efficacy, toxicity and survival of salvage peptide receptor radionuclide therapy (PRRT) with indigenous, direct-route 177Lu-labelled-DOTATATE in metastatic Nueroendocrine tumor (NET) patients who showed an objective response or disease stabilization following initial course of 177Lu-DOTATATE PRRT cycles and eventually developed progressive disease after a time-interval of more than 1 year; the variables influencing survival and response of salvage PRRT were also examined.
METHODS: A total of 26 progressive metastatic NET patients who received salvage PRRT with indigenous 177Lu-DOTATATE, were evaluated. Response was assessed under three broad categories as clinical symptomatic, biochemical and imaging (both molecular and morphological imaging). The Kaplan-Meier product-limit method was used to calculate progression-free survival (PFS) and overall survival (OS). Toxicity of salvage PRRT was evaluated by NCI-CTCAE v. 5.0 criteria (included complete blood counts, renal and liver function tests). Association between various variables and response and survival were analyzed using the χ2 test.
RESULTS: Out of the 26 patients, the complete follow-up data were not available for four patients, where only survival information was available. Thus, a total of 22 patients (median age: 55 years, range: 38-68 years, 12 men and 10 women) were included and analyzed retrospectively in study. The cumulative dose of initial course of PRRT (I-PRRT) with indigenous 177Lu-DOTATATE ranged from 800 mCi (29.6 GBq) to 1231 mCi (45.54 GBq) per patient {mean administered cumulative dose of 964 mCi (35.66 GBq) per patient}, and the salvage PRRT with indigenous 177Lu-DOTATATE comprised of a mean dose of 170 mCi (6.29GBq) per patient. The disease control rate of 68.1%, 77.3%, 63.6% and 63.6% were observed after salvage PRRT on clinical symptomatic, biochemical, molecular and morphological imaging response respectively. The median PFS after salvage PRRT was 17 months. The median OS was not attained after I-PRRT (OS-i) and salvage PRRT (OS-s). Estimated OS-i rate was 68% at 108 months and OS-s rate was 82% at 18 months. None of the patients developed Grade 3/4 hematotoxicity, nephrotoxicity and hepatotoxicity or AML/MDS after I-PRRT and salvage PRRT at median follow-up of 72 months and 12 months respectively. The highest level of toxicity was Grade 2 [seen as reversible anemia, thrombocytopenia and nephrotoxicity in 3 (13.5%), 1 (4.5%) and 2 patients (9%) respectively]. The significant p-value was not observed for any variable association.
CONCLUSION: With limited therapeutic options available for progressive NET after I-PRRT and in the absence of high-grade toxicity after 177Lu-DOTATATE salvage PRRT, retreatment with PRRT may be considered as a relatively safe therapeutic option for these patients.
ADVANCES IN KNOWLEDGE: This study examined salvage retreatment PRRT with indigenous "direct-route" 177Lu-DOTATATE and registered its safety and survival benefits, indicating this could be an effective therapeutic option in this clinical setting.
引用
- Sitani, Parghane, Talole, et al. The efficacy, toxicity and survival of salvage retreatment PRRT with 177Lu-DOTATATE in patients with progressive NET following initial course of PRRT. Br J Radiol. 2022. PMID: 35816545. doi:10.1259/bjr.20210896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。